Jennison Associates LLC Grows Position in West Pharmaceutical Services, Inc. $WST

Key Points

• Jennison Associates increased its stake in West Pharmaceutical by 46.6% in Q4 to 54,593 shares (≈$15.0M), as institutional investors now own about 93.9% of the company.
• West reported a strong quarter—EPS $2.13 vs. $1.68 expected and revenue $844.9M (up 21% YoY)—and set FY2026 guidance of $8.40–$8.75 EPS (consensus ~$8.61).
• The board approved a $1.0 billion share buyback (up to ~5.6% of shares) and declared a $0.22 quarterly dividend, while insiders disclosed modest sales (VP sold 2,817 shares; CAO sold 896 shares).

Jennison Associates LLC lifted its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 46.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,593 shares of the medical instruments supplier's stock after buying an additional 17,363 shares during the period. Jennison Associates LLC owned approximately 0.08% of West Pharmaceutical Services worth $15,021,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Wealthfront Advisers LLC lifted its holdings in West Pharmaceutical Services by 22.5% in the fourth quarter. Wealthfront Advisers LLC now owns 5,479 shares of the medical instruments supplier's stock valued at $1,507,000 after acquiring an additional 1,007 shares during the period. Torren Management LLC bought a new position in West Pharmaceutical Services in the fourth quarter valued at about $34,000. R Squared Ltd bought a new position in West Pharmaceutical Services in the fourth quarter valued at about $665,000. Comerica Bank lifted its holdings in West Pharmaceutical Services by 31.8% in the fourth quarter. Comerica Bank now owns 56,693 shares of the medical instruments supplier's stock valued at $15,599,000 after acquiring an additional 13,680 shares during the period. Finally, Anchyra Partners LLC bought a new position in West Pharmaceutical Services in the fourth quarter valued at about $611,000. Institutional investors own 93.90% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on WST shares. Weiss Ratings raised West Pharmaceutical Services from a "hold (c-)" rating to a "hold (c)" rating in a report on Monday, April 27th. Morgan Stanley set a $315.00 target price on West Pharmaceutical Services in a report on Monday, April 27th. Barclays increased their target price on West Pharmaceutical Services from $275.00 to $310.00 and gave the company an "equal weight" rating in a report on Monday, April 27th. Jefferies Financial Group reissued a "buy" rating and issued a $295.00 target price on shares of West Pharmaceutical Services in a report on Tuesday, February 10th. Finally, Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a $315.00 target price on shares of West Pharmaceutical Services in a report on Friday, February 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $322.89.

Insider Activity

In related news, VP Annette F. Favorite sold 2,817 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $305.20, for a total transaction of $859,748.40. Following the sale, the vice president owned 16,828 shares of the company's stock, valued at approximately $5,135,905.60. This trade represents a 14.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Chad Winters sold 896 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $300.67, for a total value of $269,400.32. Following the sale, the chief accounting officer directly owned 1,523 shares in the company, valued at $457,920.41. This trade represents a 37.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.60% of the stock is owned by company insiders.

West Pharmaceutical Services Stock Up 1.0%

NYSE WST opened at $300.55 on Friday. The stock's 50-day moving average price is $257.16 and its 200-day moving average price is $263.24. The company has a quick ratio of 2.04, a current ratio of 2.71 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a 52 week low of $202.79 and a 52 week high of $322.34. The company has a market capitalization of $21.23 billion, a P/E ratio of 40.18, a price-to-earnings-growth ratio of 2.51 and a beta of 1.17.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last posted its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $2.13 EPS for the quarter, topping the consensus estimate of $1.68 by $0.45. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The firm had revenue of $844.90 million for the quarter, compared to the consensus estimate of $779.68 million. During the same quarter last year, the company earned $1.45 earnings per share. The business's revenue for the quarter was up 21.0% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. On average, equities research analysts predict that West Pharmaceutical Services, Inc. will post 8.61 earnings per share for the current year.

West Pharmaceutical Services Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 6th. Stockholders of record on Wednesday, April 29th will be paid a $0.22 dividend. The ex-dividend date of this dividend is Wednesday, April 29th. This represents a $0.88 annualized dividend and a dividend yield of 0.3%. West Pharmaceutical Services's dividend payout ratio (DPR) is 11.76%.

West Pharmaceutical Services announced that its Board of Directors has initiated a stock repurchase plan on Tuesday, February 17th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the medical instruments supplier to reacquire up to 5.6% of its shares through open market purchases. Shares buyback plans are often a sign that the company's management believes its shares are undervalued.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.